Mass General
The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.
ACMG Presentation Highlights Broad Institute's Massive Expansion of COVID-19 Testing Program
The Broad's clinical research sequencing lab now runs 135,000 tests each day and routinely tests more than 100 higher education sites and 40 schools in the state.
Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.
In Fight Against Coronavirus, Developers Turn to Emerging, As Well As Established, Technologies
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.
Natera, MGH to Collaborate in Early-Stage Breast Cancer Clinical Trial of Targeted Therapy
The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.